- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/50 - Ketonic radicals
Patent holdings for IPC class C07D 213/50
Total number of patents in this class: 240
10-year publication summary
|
24
|
30
|
13
|
16
|
17
|
15
|
7
|
5
|
8
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 171 |
9 |
| Syngenta Limited | 456 |
7 |
| PTC Therapeutics, Inc. | 483 |
6 |
| Mycovia Pharmaceuticals, Inc. | 41 |
6 |
| Chem-Master International, Inc. | 11 |
5 |
| Givaudan SA | 1861 |
5 |
| Johnson Matthey Public Limited Company | 1851 |
5 |
| Centre National de La Recherche Scientifique | 10421 |
4 |
| The Board of Trustees of the University of Illinois | 2687 |
4 |
| Purdue Pharma L.P. | 499 |
4 |
| Lighthouse Pharmaceuticals, Inc. | 10 |
4 |
| The Regents of the University of California | 19898 |
3 |
| Syngenta Crop Protection AG | 6045 |
3 |
| Epizyme, Inc. | 370 |
3 |
| Karyopharm Therapeutics Inc. | 142 |
3 |
| The Research Foundation for The State University of New York | 1616 |
3 |
| The Research Foundation of State University of New York | 449 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2848 |
3 |
| Xenthera, Inc. | 4 |
3 |
| Syngenta Participations AG | 1903 |
2 |
| Other owners | 155 |